| Medical and Health Sciences | 2021-2025 | 33 | US 15 | 99.99 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 41 | US 22 | 99.86 |
| Cardiology and Cardiovascular Medicine | Lifetime | 404 | US 226 | 99.46 |
| Nephrology | Lifetime | 999 | US 442 | 79.68 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 5 | US 3 | 99.97 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 43 | US 27 | 99.84 |
| Surgery | 2021-2025 | 422 | US 168 | 96.70 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 8 | US 5 | 99.71 |
| Diabetes Treatment and Management | Lifetime | 34 | US 19 | 99.82 |
| Cardiovascular Function and Risk Factors | Lifetime | 99 | US 67 | 99.79 |
| Diabetes Management and Research | Lifetime | 70 | US 38 | 99.63 |
| Heart Failure Treatment and Management | Lifetime | 80 | US 48 | 99.70 |
| Potassium and Related Disorders | Lifetime | 26 | US 17 | 99.37 |
| Metabolism, Diabetes, and Cancer | Lifetime | 182 | US 82 | 99.15 |
| Pancreatic function and diabetes | Lifetime | 347 | US 159 | 98.92 |
| Acute Myocardial Infarction Research | Lifetime | 590 | US 267 | 98.25 |
| Erythropoietin and Anemia Treatment | Lifetime | 173 | US 74 | 97.05 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 813 | US 329 | 97.43 |
| Pharmacology and Obesity Treatment | Lifetime | 303 | US 137 | 96.63 |
| Electrolyte and hormonal disorders | Lifetime | 702 | US 332 | 94.82 |
| Magnesium in Health and Disease | Lifetime | 850 | US 302 | 83.36 |
| Intravenous Infusion Technology and Safety | Lifetime | 302 | US 93 | 61.04 |
| Diabetes Treatment and Management | 2021-2025 | 4 | US 3 | 99.97 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 8 | US 6 | 99.96 |
| Heart Failure Treatment and Management | 2021-2025 | 7 | US 4 | 99.92 |
| Pancreatic function and diabetes | 2021-2025 | 11 | US 5 | 99.71 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 8 | US 5 | 99.66 |
| Potassium and Related Disorders | 2021-2025 | 11 | US 7 | 99.19 |
| Diabetes Management and Research | 2021-2025 | 190 | US 102 | 97.37 |
| Diet and metabolism studies | 2021-2025 | 721 | US 217 | 93.82 |
| Pharmacology and Obesity Treatment | 2021-2025 | 63 | US 29 | 94.17 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 393 | US 100 | 91.72 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 545 | US 172 | 90.42 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 667 | US 165 | 89.33 |
| Electrolyte and hormonal disorders | 2021-2025 | 271 | US 86 | 81.24 |
| Diabetes Management and Education | 2021-2025 | 695 | US 208 | 77.99 |
| Clinical practice guidelines implementation | 2021-2025 | 508 | US 96 | 76.02 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 679 | US 245 | 66.97 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 681 | US 176 | 58.59 |
| GDF15 and Related Biomarkers | 2021-2025 | 771 | US 194 | 48.06 |
| Apelin-related biomedical research | 2021-2025 | 534 | US 83 | 47.37 |
